Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Net sales were at the same level as in the corresponding period of the previous year. The operating loss widened because selling, general and administrative expenses increased, mainly due to the one-time recording of ¥96 million in production transfer costs associated with the change in manufacturing contractors. The ordinary loss resulted from factors including the recording of ¥29 million in income, including proceeds from AMED's research and development support program, while ¥10 million in financing-related costs was recorded.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥92 million (YoY 0.0%) |
| Operating profit | ¥-245 million |
| Ordinary income | ¥-228 million |
| Profit attributable to owners of the parent | ¥-228 million |
| Net income per share | -¥6.55 |
| Equity ratio | End of the current fiscal period 59.5 / End of previous period 54.1 |
| Total assets | ¥5,392 million |
| Net assets | ¥3,217 million |
| Full-year earnings forecast | Net Sales ¥1,038 million (YoY +221.0%) / Operating profit ¥-696 million / Ordinary income ¥-625 million / Net income ¥-628 million |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥7,063 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Issuance of new shares and stock acquisition rights through a third-party allotment. The Company resolved to conduct its third third-party allotment, with 31 August 2026 as the payment and allotment date, and plans to issue 1,000,000 new shares and 10,500 stock acquisition rights. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 36,034,100 |
| Treasury Shares at Period-End | 16,107 |
| Factors Behind Changes in Business Performance | Net sales were at the same level as in the corresponding period of the previous year. The operating loss widened because selling, general and administrative expenses increased, mainly due to the one-time recording of ¥96 million in production transfer costs associated with the change in manufacturing contractors. The ordinary loss resulted from factors including the recording of ¥29 million in income, including proceeds from AMED's research and development support program, while ¥10 million in financing-related costs was recorded. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Selling, general and administrative expenses increased mainly because ¥96 million in production transfer costs associated with the change in manufacturing contractors was recorded as a one-time expense. For the ordinary loss, income of ¥29 million, including proceeds from being selected for AMED's research and development support program, was recorded, while ¥10 million in financing-related costs was recorded.